Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Questions About Treating Patients Using a CDK4/6 Inhibitor

Conference CorrespondentĀ  - Breast Cancer, Video, SABCS
Matthew P. Goetz, MD

Dr Matthew Goetz addresses common questions that arise when patients with HER+ metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.

Related Items
What is Minimal Residual Disease (MRD) Negativity?
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Multiple Myeloma as a Chronic Disease
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Triplets versus Quads
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
CAR T-Cell Data in Multiple Myeloma
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Latest Developments in Multiple Myeloma
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Breast Cancer
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Updates
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Updates, In the News
Last modified: April 27, 2020